Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

Dancing with the Flu

Innovation at Genentech often starts with a “What if?” Gerry Nakamura and Lee Swem* talk about what would happen if we could neutralize all known strains of the flu.
*While Lee was an employee at the time this article was published, he has since left Genentech.

“Bundle up, rest, and drink plenty of fluids.” If you’ve ever had the flu, you’ve been given that age-old advice. After a few days of feeling awful and a whole lot of daytime television, most people are back on their feet. But what about the people who develop severe, life-threatening influenza? This was the question that led Genentech’s infectious disease team to start their search for more comprehensive flu care. 

“Anytime we make a neutralizing antibody, the flu changes and evolves in order to evade our immune system,” says Lee Swem, Infectious Disease Scientist. So how do you isolate a biological master of disguise? Lee and the rest of the team began devising methods to fight the flu no matter how it tried to hide.

Previous research had shown that a part of a crucial protein in the flu virus — Hemagglutinin — remained the same throughout the virus’ evolution. The team decided to find an antibody that could bind to this conserved epitope from among human blood samples. Cloning that antibody could hypothetically allow them to neutralize the flu virus in all its forms.

From there the hunt was on. According to Antibody Engineer Gerry Nakamura, “The cell that makes that particular antibody—which is called a ‘B cell’—should be circulating within all of us. The trick was finding it.” With the help of volunteers, some truly inspiring lab work, and an actual bucket brigade to help get the time-sensitive cells to the lab, their results so far look promising. What’s more, the application of this new methodology may help identify therapeutic antibodies in other disease fields as well.

For more on the team’s efforts, watch our “Dancing with the Flu” video.

Big Ideas

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Health Equity
  • Advancing Inclusive Research
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Genentech Patient Foundation
  • Understanding Insurance
  • Medicine Information Support
  • Clinical Trial Information
  • Advancing Inclusive Research
  • Our Approach to Pricing
  • Patient Advocacy
  • Create With Us
  • Disease Education
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • —
  • Privacy Policy
  • Terms & Conditions
  • Accessibility
© 2023 Genentech, Inc. All rights reserved. This site is intended for US residents only.